Value Investing News

Acadia Pharmaceuticals is a small development-stage drug firm, focused on a single late stage candidate for treatment of psychosis stemming from Parkinson's disease. The loss of their development partner, setbacks in Phase III trials, and a poor history of success makes this one risky investment.

• http://www.magicdiligence.com/articles/acadia-pharmaceuticals-2011-06 (200)